异基因造血干细胞移植后非感染性肺部并发症的前瞻性研究
该研究前瞻性纳入法国某大学教学医院2006至2008年间接受异基因HSCT且第100天存活的患者198例,中位随访72.3个月,43例共诊断55例次迟发性非感染性肺部并发症(LONIPCs),36个月累积发生率为19.8%(95%CI 14.2-25.3%),并识别出移植前胸部放疗史、移植后100天内肺炎史及第100天低FEF25-75%为危险因素。
要点
- 异基因HSCT后LONIPCs的36个月累积发生率为19.8%(95%CI 14.2-25.3%)。
- 闭塞性细支气管炎综合征(n=22)和间质性肺病(n=12)是最常见的LONIPCs。
- 移植前胸部放疗史、移植后100天内肺炎史及第100天低FEF25-75%与LONIPCs发生相关。
核心结论
- 异基因HSCT后LONIPCs并不少见,36个月累积发生率为19.8%(95%CI 14.2-25.3%)。
- 移植前胸部放疗史、移植后100天内肺炎史及第100天低FEF25-75%与LONIPCs发生独立相关。
研究设计与样本
- 前瞻性研究,筛选2006至2008年法国某大学教学医院连续接受异基因HSCT的患者243例,纳入第100天存活者198例进行分析。
- 中位(四分位距)随访时间为72.3(15.2-88.5)个月。
主要发现
- 43例患者共诊断55例次LONIPCs,其中闭塞性细支气管炎综合征n=22、间质性肺病n=12为最常见类型。
- 纳入后36个月LONIPCs估计累积发生率为19.8%(95%CI 14.2-25.3%)。
- 诊断LONIPCs后估计中位生存期为78.5个月(95%CI 20.0-未达到)。
- 多因素Cox模型显示,移植前任何时间胸部放疗史、移植后100天内肺炎史及第100天低FEF25-75%与LONIPCs发生相关。
临床怎么用
- 对具有移植前胸部放疗史、移植后100天内肺炎史或第100天低FEF25-75%的患者应加强监测,以便早期治疗或预防性治疗LONIPCs。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epidemiological data on late-onset noninfectious pulmonary complications (LONIPCs) following allogeneic haematopoietic stem cell transplantation (HSCT) are derived exclusively from retrospective studies and are conflicting. We aimed to evaluate prospectively the incidence, risk factors and outcomes for LONIPCs.All consecutive patients scheduled to receive allogeneic HSCT between 2006 and 2008 at a university teaching hospital in France were screened for inclusion in the study. Eligible patients were those surviving at day 100. Among 243 screened patients, 198 patients were included in the analysis. The median (interquartile range) follow-up was 72.3 (15.2-88.5) months. 55 LONIPCs were diagnosed in 43 patients. Bronchiolitis obliterans syndrome (n=22) and interstitial lung disease (n=12) were the most common LONIPCs. At 36 months after inclusion, the estimated cumulative incidence of LONIPCs was 19.8% (95% CI 14.2-25.3%). The estimated median survival after the diagnosis of LONIPCs was 78.5 months (95% CI 20.0-not reached). Based on a multivariate Cox model, a history of chest irradiation anytime prior to HSCT, a history of pneumonia within 100 days post-HSCT and a low mean forced expiratory flow at 25-75% of forced vital capacity at day 100 were associated with the development of LONIPCs.Our data provide clues to identify patients at high risk of developing LONIPCs. These patients should be targeted for close monitoring to provide earlier LONIPC treatment or prophylactic treatment.
引用
- Bergeron A, Chevret S, Peffault de Latour R, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018. PMID: 29650555. doi:10.1183/13993003.02617-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。